The MINT Clinical Trial for Myositis Patients with Interstitial Lung Disease (ILD)

Dr. Rohit Aggarwal joins MSU for a webinar about The MINT Clinical Trial for Myositis Patients with Interstitial Lung Disease (ILD).
If you have been diagnosed with pulmonary fibrosis, also known as Interstitial Lung Disease (ILD), and you also have myositis (such as polymyositis, dermatomyositis, or anti-synthetase syndrome) or positive myositis autoantibodies, you may be eligible to take part in a research study called MINT.
The goal of this study is to gain a better understanding of how anti-fibrotic drugs can help treat myositis associated with ILD. The study will focus on the drug Nintedanib (brand name Ofev®), an oral anti-fibrotic medication approved by the Food and Drug Administration (FDA) for the treatment of various types of ILD.
The exciting part is that this clinical trial is unique because you won’t need to visit a study center. You can participate in the study from the comfort of your own home. No need to worry about traveling long distances or spending time away from your surroundings.
Is this study right for you? Watch the webinar to find out and have your questions answered.